Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024..
BACKGROUND: Protein-based vaccines for COVID-19 provide a traditional vaccine platform with long-lasting protection for non-SARS-CoV-2 pathogens and may complement messenger RNA vaccines as a booster dose. While NVX-CoV2373 showed substantial early efficacy, the durability of protection has not been delineated.
METHODS: The PREVENT-19 vaccine trial employed a blinded crossover design; the original placebo arm received NVX-CoV2373 after efficacy was established. Using novel statistical methods that integrate surveillance data of circulating strains with post-crossover cases, we estimated placebo-controlled vaccine efficacy and durability of NVX-CoV2373 against both pre-Delta and Delta strains of SARS-CoV-2.
RESULTS: Vaccine efficacy against pre-Delta strains of COVID-19 was 89% (95% CI: 75%, 95%) and 87% (72%, 94%) at 0 and 90 days after 2 doses of NVX-CoV2373, respectively, with no evidence of waning (p=0.93). Vaccine efficacy against the Delta strain was 88% (71%, 95%), 82% (56%, 92%), and 77% (44%, 90%) at 40, 120, and 180 days, respectively, with evidence of waning (p<0.01). In sensitivity analyses, the estimated Delta vaccine efficacy at 120 days ranged from 66% (15%, 86%) to 89% (74%, 95%) per various assumptions of the surveillance data.
CONCLUSION: NVX-CoV2373 has high initial efficacy against pre-Delta and Delta strains of COVID-19 with little evidence of waning for pre-Delta strains through 90 days and moderate waning against Delta strains over 180 days.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2024) vom: 19. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Follmann, Dean [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 19.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciae081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368624528 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368624528 | ||
| 003 | DE-627 | ||
| 005 | 20240219232236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciae081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM368624528 | ||
| 035 | |a (NLM)38372392 | ||
| 035 | |a (PII)ciae081 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Follmann, Dean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024. | ||
| 520 | |a BACKGROUND: Protein-based vaccines for COVID-19 provide a traditional vaccine platform with long-lasting protection for non-SARS-CoV-2 pathogens and may complement messenger RNA vaccines as a booster dose. While NVX-CoV2373 showed substantial early efficacy, the durability of protection has not been delineated | ||
| 520 | |a METHODS: The PREVENT-19 vaccine trial employed a blinded crossover design; the original placebo arm received NVX-CoV2373 after efficacy was established. Using novel statistical methods that integrate surveillance data of circulating strains with post-crossover cases, we estimated placebo-controlled vaccine efficacy and durability of NVX-CoV2373 against both pre-Delta and Delta strains of SARS-CoV-2 | ||
| 520 | |a RESULTS: Vaccine efficacy against pre-Delta strains of COVID-19 was 89% (95% CI: 75%, 95%) and 87% (72%, 94%) at 0 and 90 days after 2 doses of NVX-CoV2373, respectively, with no evidence of waning (p=0.93). Vaccine efficacy against the Delta strain was 88% (71%, 95%), 82% (56%, 92%), and 77% (44%, 90%) at 40, 120, and 180 days, respectively, with evidence of waning (p<0.01). In sensitivity analyses, the estimated Delta vaccine efficacy at 120 days ranged from 66% (15%, 86%) to 89% (74%, 95%) per various assumptions of the surveillance data | ||
| 520 | |a CONCLUSION: NVX-CoV2373 has high initial efficacy against pre-Delta and Delta strains of COVID-19 with little evidence of waning for pre-Delta strains through 90 days and moderate waning against Delta strains over 180 days | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a NVX-CoV2373 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a vaccine durability | |
| 700 | 1 | |a Mateja, Allyson |e verfasserin |4 aut | |
| 700 | 1 | |a Fay, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Magaret, Craig A |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yunda |e verfasserin |4 aut | |
| 700 | 1 | |a Fong, Youyi |e verfasserin |4 aut | |
| 700 | 1 | |a Angier, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Nason, Martha |e verfasserin |4 aut | |
| 700 | 1 | |a Gay, Cynthia L |e verfasserin |4 aut | |
| 700 | 1 | |a Kotloff, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Wayne |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Iksung |e verfasserin |4 aut | |
| 700 | 1 | |a Dunkle, Lisa M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2024) vom: 19. Feb. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciae081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 02 | ||